

Confirmation of Registration



February 13 , 2024

Dear Klytaimnistra Giannaki,

We hereby confirm your registration for the ESN-HSN Meeting 2025. See you soon in Naxos, Greece!

Should you have any questions or need further assistance, please do not hesitate to contact us:

Secretariat, ESN-HSN Naxos 2025 Meeting

Attn: Emmanouella Tsirimonaki, MSc,

esn-hsn_naxos2025secretariat@outlook.com

ESN is a registered charity in England and Wales, Company no. 1098662
Registered office: University of Bradford, Faculty of Life Sciences, Richmond Road, Bradford
BD7 1DP, UK.

ANALYSIS OF DIFFERENTIAL EXPRESSION OF GENES IN CELLULAR MODELS FOR THE STUDY OF ALZHEIMER'S DISEASE

Klytaimnistra Giannaki^{1,3}, Aristeia Volioti¹, Effrosyni Aktypi¹, Tatiani Koukovini¹,
Elisavet Sfouni¹, Charikleia Triantafyllou¹, Alexandros Galaras^{2,4}, Pantelis Hatzis²,
Panagiota Papazafiri¹, Spiros Efthimiopoulos^{1,3}

¹Section of Human and Animal Physiology, Department of Biology, School of Science,
National and Kapodistrian University of Athens, Greece

²Biomedical Sciences Research Center "Alexander Fleming" Vari, Greece

³Athens International Master's Programme in Neurosciences, Athens, Greece

⁴Department of Biochemistry and Biotechnology, University of Thessaly, Larissa,
Greece

Alzheimer's disease (AD) is a neurodegenerative disorder, with both familial and sporadic incidence. Mutations in the genes encoding for the Amyloid Precursor Protein (APP), and Presenilin 1 (PSEN1), which is part of the γ -secretase complex that cleaves APP and releases the toxic A β peptide, cause early onset AD. The physiological role of these proteins is however not completely elucidated.

In order to determine the functions and processes of these proteins, we established cells lines, knockout (KO) for Amyloid Precursor Protein (APPKO) and Presenilin 1 (PSEN1KO), and alpha-synuclein (SNCAKO) as a specificity control for AD related changes. The KOs were obtained using the CRISPR Cas9 system with 2 single-guide RNAs, and validated by PCR and Western Blot.

Based on our hypothesis that mutations in the APP and PSEN1 genes lead to a disturbance in neurotrophic processes and in the response to neurotoxic insults, we examined the response of these cells to H₂O₂ (oxidative stress) and CoCl₂ (chemical hypoxia) using the MTT assay. Our results show that our cells were resistant to these treatments.

KEGG and GO analysis after RNA sequencing showed that the genes that have changed their expression in the APPKO and PSEN1KO cell lines but not in the SNCAKO cell line are involved mainly in brain development processes. We therefore hypothesise that early on in development the mutations may trigger the disease processes and we propose that some of the differentially expressed genes may be potential biomarkers.